Tirzepatides 2.0%-2.5% mean HbA1c reduction in SURPASS studies outperformed semaglutide by roughly 0.5 percentage points, prompting Mexicos regulator to authorize the drug for obesity in 2024
Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9 th edition
BPC-157 is one of the most-discussed peptides in active-expat circles in the UAE, and it sits in one of the more honest grey zones in modern clinical medicine
List of GLP-1 ini6al approvals since 2005 *products no longer on the market Notable GLP-1 Agonists for Obesity The first GLP-1 drug approved for obesity was Saxenda (liraglutide) from Novo Nordisk, a twice-daily injectable that demonstrated a 7% weight reduction over a year upon its approval
This is where the name GHK-Cu comes from: Glycine, Histidine, K (the one-letter abbreviation for lysine), and Cu, the chemical symbol for copper
For research applications only in qualified laboratory settings